David Edward Sloane, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Drug Hypersensitivity | 8 | 2020 | 923 | 1.210 |
Why?
|
| Desensitization, Immunologic | 8 | 2020 | 558 | 1.070 |
Why?
|
| Connective Tissue Diseases | 1 | 2019 | 285 | 0.520 |
Why?
|
| Basophils | 2 | 2008 | 407 | 0.450 |
Why?
|
| Antibodies, Monoclonal | 6 | 2019 | 9263 | 0.410 |
Why?
|
| Allergens | 1 | 2017 | 1443 | 0.340 |
Why?
|
| Stanozolol | 2 | 2008 | 3 | 0.320 |
Why?
|
| Receptors, IgE | 2 | 2012 | 375 | 0.290 |
Why?
|
| Angioedema | 1 | 2007 | 184 | 0.250 |
Why?
|
| Receptors, Immunologic | 3 | 2008 | 1418 | 0.230 |
Why?
|
| Androgens | 2 | 2008 | 1281 | 0.210 |
Why?
|
| Immunoglobulin E | 2 | 2012 | 1506 | 0.210 |
Why?
|
| Skull Neoplasms | 1 | 2003 | 173 | 0.200 |
Why?
|
| Sphenoid Bone | 1 | 2003 | 176 | 0.200 |
Why?
|
| Nasal Obstruction | 1 | 2003 | 163 | 0.190 |
Why?
|
| Chondrosarcoma | 1 | 2003 | 306 | 0.180 |
Why?
|
| Receptors, Fc | 1 | 2004 | 537 | 0.180 |
Why?
|
| Antineoplastic Agents | 5 | 2020 | 13676 | 0.160 |
Why?
|
| Inflammation | 1 | 2019 | 10873 | 0.160 |
Why?
|
| Mouth Diseases | 1 | 2001 | 239 | 0.160 |
Why?
|
| Skin Tests | 3 | 2017 | 639 | 0.160 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2008 | 2433 | 0.160 |
Why?
|
| Asthma | 1 | 2017 | 6291 | 0.150 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2008 | 2892 | 0.150 |
Why?
|
| Histamine Release | 2 | 2008 | 134 | 0.130 |
Why?
|
| Sinusitis | 1 | 2003 | 997 | 0.110 |
Why?
|
| Food Hypersensitivity | 1 | 2001 | 734 | 0.110 |
Why?
|
| Respiratory Sounds | 1 | 2017 | 702 | 0.110 |
Why?
|
| Neoplasms | 3 | 2019 | 22371 | 0.110 |
Why?
|
| Clinical Clerkship | 1 | 2016 | 569 | 0.090 |
Why?
|
| Dyspnea | 1 | 2017 | 1352 | 0.080 |
Why?
|
| Educational Measurement | 1 | 2016 | 1260 | 0.080 |
Why?
|
| N-Formylmethionine Leucyl-Phenylalanine | 1 | 2008 | 221 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-cbl | 1 | 2008 | 120 | 0.070 |
Why?
|
| Immune Sera | 1 | 2008 | 605 | 0.070 |
Why?
|
| Drug Eruptions | 1 | 2010 | 335 | 0.070 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2016 | 1085 | 0.070 |
Why?
|
| Angioedemas, Hereditary | 1 | 2008 | 91 | 0.070 |
Why?
|
| Serpins | 1 | 2008 | 246 | 0.070 |
Why?
|
| Progesterone | 1 | 2010 | 752 | 0.070 |
Why?
|
| General Surgery | 1 | 2016 | 1720 | 0.060 |
Why?
|
| Organoplatinum Compounds | 2 | 2020 | 408 | 0.060 |
Why?
|
| Infertility, Female | 1 | 2010 | 763 | 0.060 |
Why?
|
| Milk, Human | 1 | 2008 | 490 | 0.050 |
Why?
|
| Interleukin-4 | 2 | 2004 | 1156 | 0.050 |
Why?
|
| Serine Endopeptidases | 1 | 2008 | 1027 | 0.050 |
Why?
|
| Down-Regulation | 2 | 2008 | 2937 | 0.050 |
Why?
|
| Leukotrienes | 1 | 2004 | 232 | 0.050 |
Why?
|
| Health Care Costs | 1 | 2016 | 3239 | 0.050 |
Why?
|
| Fertilization in Vitro | 1 | 2010 | 1303 | 0.050 |
Why?
|
| Diagnosis, Differential | 1 | 2017 | 13014 | 0.050 |
Why?
|
| Humans | 18 | 2020 | 768166 | 0.040 |
Why?
|
| Clinical Competence | 1 | 2016 | 4858 | 0.040 |
Why?
|
| Cells, Cultured | 2 | 2008 | 19015 | 0.040 |
Why?
|
| Taxoids | 2 | 2012 | 667 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 2008 | 6514 | 0.040 |
Why?
|
| Eosinophils | 1 | 2003 | 952 | 0.040 |
Why?
|
| Adult | 6 | 2017 | 223646 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2007 | 10760 | 0.040 |
Why?
|
| Female | 9 | 2017 | 397192 | 0.030 |
Why?
|
| Kinetics | 1 | 2004 | 6329 | 0.030 |
Why?
|
| Lipids | 1 | 2007 | 3343 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2019 | 41754 | 0.030 |
Why?
|
| Leukocytes | 1 | 2004 | 2035 | 0.030 |
Why?
|
| Syndrome | 1 | 2001 | 3272 | 0.030 |
Why?
|
| Aged | 5 | 2016 | 171504 | 0.030 |
Why?
|
| Accreditation | 1 | 2016 | 476 | 0.030 |
Why?
|
| Medical History Taking | 1 | 2016 | 779 | 0.030 |
Why?
|
| Radiography | 1 | 2003 | 6983 | 0.030 |
Why?
|
| Liver | 1 | 2007 | 7577 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2008 | 5703 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2016 | 65371 | 0.020 |
Why?
|
| Retrospective Studies | 4 | 2020 | 81762 | 0.020 |
Why?
|
| Physical Examination | 1 | 2016 | 1263 | 0.020 |
Why?
|
| Middle Aged | 4 | 2016 | 223492 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 2007 | 59629 | 0.020 |
Why?
|
| Motivation | 1 | 2020 | 2020 | 0.020 |
Why?
|
| Schools, Medical | 1 | 2016 | 883 | 0.020 |
Why?
|
| Male | 6 | 2016 | 364719 | 0.020 |
Why?
|
| Animals | 2 | 2019 | 169246 | 0.020 |
Why?
|
| alpha-2-Antiplasmin | 1 | 2008 | 13 | 0.020 |
Why?
|
| Proteinase Inhibitory Proteins, Secretory | 1 | 2008 | 49 | 0.020 |
Why?
|
| Oxymetholone | 1 | 2008 | 8 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2003 | 9384 | 0.020 |
Why?
|
| Antithrombin III | 1 | 2008 | 128 | 0.020 |
Why?
|
| Danazol | 1 | 2008 | 44 | 0.020 |
Why?
|
| alpha 1-Antitrypsin | 1 | 2008 | 169 | 0.020 |
Why?
|
| Estrogen Antagonists | 1 | 2008 | 151 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2009 | 696 | 0.020 |
Why?
|
| Antigens | 1 | 2012 | 1442 | 0.020 |
Why?
|
| Cisplatin | 1 | 2012 | 1660 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2008 | 1730 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2007 | 39348 | 0.020 |
Why?
|
| Mast Cells | 1 | 2012 | 1406 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2008 | 23645 | 0.010 |
Why?
|
| Chromatography, Liquid | 1 | 2008 | 996 | 0.010 |
Why?
|
| Massachusetts | 1 | 2016 | 8890 | 0.010 |
Why?
|
| Inflammation Mediators | 1 | 2012 | 1892 | 0.010 |
Why?
|
| Students, Medical | 1 | 2016 | 1964 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 2 | 2012 | 7477 | 0.010 |
Why?
|
| Sepharose | 1 | 2003 | 102 | 0.010 |
Why?
|
| Leukotriene C4 | 1 | 2003 | 79 | 0.010 |
Why?
|
| Clinical Protocols | 1 | 2008 | 1443 | 0.010 |
Why?
|
| Mass Spectrometry | 1 | 2008 | 2202 | 0.010 |
Why?
|
| Databases, Factual | 1 | 2016 | 8080 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2008 | 5027 | 0.010 |
Why?
|
| Interleukin-12 | 1 | 2003 | 577 | 0.010 |
Why?
|
| Cross-Linking Reagents | 1 | 2003 | 693 | 0.010 |
Why?
|
| Pregnancy Outcome | 1 | 2010 | 2972 | 0.010 |
Why?
|
| Calcium | 1 | 2012 | 5792 | 0.010 |
Why?
|
| Autoimmune Diseases | 1 | 2010 | 2257 | 0.010 |
Why?
|
| Cytoplasm | 1 | 2003 | 1505 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2008 | 13421 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2008 | 17622 | 0.010 |
Why?
|
| Lipid Metabolism | 1 | 2003 | 1904 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2003 | 2885 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2003 | 5902 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 2003 | 3711 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2008 | 8054 | 0.010 |
Why?
|
| Young Adult | 1 | 2016 | 60066 | 0.010 |
Why?
|
| Pregnancy | 1 | 2010 | 30256 | 0.000 |
Why?
|
| Mice | 1 | 2012 | 82029 | 0.000 |
Why?
|
| Time Factors | 1 | 2003 | 40218 | 0.000 |
Why?
|
| Child | 1 | 2008 | 80917 | 0.000 |
Why?
|